PDCD1 and metabolic dysfunction-associated steatotic liver disease: Moreover, it has been observed in preclinical models and patients of MASLD or MASH treated with PD-1-direct antibodies that CD8+ PD1+ CXCR6+ lymphocytes showed impaired hepatic immune surveillance, and they also contribute to the progression of tissue damage [122] (Figure 3).